Trending...
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
SAN DIEGO & LORDSTOWN, Ohio--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Kadmon Holdings, Inc. (NASDAQ: KDMN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 1, 2020 and March 10, 2021. Kadmon is a biopharmaceutical company that develops small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Kadmon's lead product candidate includes belumosudil (KD025), which is in Phase II clinical development for the treatment of chronic graft-versus-host disease ("cGVHD").
If you suffered a loss due to Kadmon Holdings, Inc.'s misconduct, click here.
Kadmon Holdings, Inc. (KDMN) Misled Investors Regarding its New Drug Submission for its Lead Drug Candidate
More on Ohio Pen
According to the complaint, on September 30, 2020, Kadmon announced the submission of a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD with the U.S. Drug and Food Administration ("FDA"). On November 30, 2020, Kadmon announced the FDA's acceptance of the NDA and that the FDA had assigned the NDA a Prescription Drug User Fee Act [PDUFA] target date of May 30, 2021. Throughout the class period, Kadmon touted the drug's trial milestones and efficacy. However, the Company failed to disclose that the NDA was incomplete and/or deficient when submitted and the additional data submitted in support of the NDA materially altered the initial submission, and therefore, the PDUFA target date.
On March 10, 2021, Kadmon announced that the FDA "has extended the review period" for the NDA and that, "[i]n a notice received from the FDA on March 9, 2021, the Company was informed that the [PDUFA] goal date for its Priority Review of belumosudil has been extended to August 30, 2021." Kadmon advised investors that "[t]he FDA extended the PDUFA date to allow time to review additional information submitted by Kadmon in response to a recent FDA information request," and that "[t]he submission of the additional information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA date by three months." On this news, Kadmon's stock price fell $0.52 per share, or 10.57%, to close at $4.40 per share on March 11, 2021. The stock continues to decline.
More on Ohio Pen
If you purchased shares of Kadmon Holdings, Inc. (KDMN) between October 1, 2020 and March 10, 2021, you have until June 2, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kadmon Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
If you suffered a loss due to Kadmon Holdings, Inc.'s misconduct, click here.
Kadmon Holdings, Inc. (KDMN) Misled Investors Regarding its New Drug Submission for its Lead Drug Candidate
More on Ohio Pen
- World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
According to the complaint, on September 30, 2020, Kadmon announced the submission of a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD with the U.S. Drug and Food Administration ("FDA"). On November 30, 2020, Kadmon announced the FDA's acceptance of the NDA and that the FDA had assigned the NDA a Prescription Drug User Fee Act [PDUFA] target date of May 30, 2021. Throughout the class period, Kadmon touted the drug's trial milestones and efficacy. However, the Company failed to disclose that the NDA was incomplete and/or deficient when submitted and the additional data submitted in support of the NDA materially altered the initial submission, and therefore, the PDUFA target date.
On March 10, 2021, Kadmon announced that the FDA "has extended the review period" for the NDA and that, "[i]n a notice received from the FDA on March 9, 2021, the Company was informed that the [PDUFA] goal date for its Priority Review of belumosudil has been extended to August 30, 2021." Kadmon advised investors that "[t]he FDA extended the PDUFA date to allow time to review additional information submitted by Kadmon in response to a recent FDA information request," and that "[t]he submission of the additional information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA date by three months." On this news, Kadmon's stock price fell $0.52 per share, or 10.57%, to close at $4.40 per share on March 11, 2021. The stock continues to decline.
More on Ohio Pen
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- Rx Processing Corp.com The Forth Of July 2025
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
If you purchased shares of Kadmon Holdings, Inc. (KDMN) between October 1, 2020 and March 10, 2021, you have until June 2, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kadmon Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Champions Group Expands Midwest Presence with Acquisition of McAfee Heating and Air Conditioning
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- "Drink Like It's 1776… Just Kidding, It's 1932." A Golden Age Patriotic Pop-Up
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Nationwide Completes Acquisition of Allstate Employer Stop Loss Business for $1.25 billion
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT